+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Synovial Sarcoma - Pipeline Review, H1 2020

  • ID: 5007669
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 359 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Apollomics Inc
  • Cue Biopharma Inc
  • Epizyme Inc
  • Immunocore Ltd
  • MediGene AG
  • Pfizer Inc
  • MORE
Synovial Sarcoma - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H1 2020, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 10, 8 and 1 respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Apollomics Inc
  • Cue Biopharma Inc
  • Epizyme Inc
  • Immunocore Ltd
  • MediGene AG
  • Pfizer Inc
  • MORE
  • Introduction
  • Synovial Sarcoma - Overview
  • Synovial Sarcoma - Therapeutics Development
  • Synovial Sarcoma - Therapeutics Assessment
  • Synovial Sarcoma - Companies Involved in Therapeutics Development
  • Synovial Sarcoma - Drug Profiles
  • Synovial Sarcoma - Dormant Projects
  • Synovial Sarcoma - Discontinued Products
  • Synovial Sarcoma - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Synovial Sarcoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Synovial Sarcoma - Pipeline by Accuronix Therapeutics Inc, H1 2020
  • Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
  • Synovial Sarcoma - Pipeline by Advenchen Laboratories LLC, H1 2020
  • Synovial Sarcoma - Pipeline by Apollomics Inc, H1 2020
  • Synovial Sarcoma - Pipeline by Biogenera SpA, H1 2020
  • Synovial Sarcoma - Dormant Projects, H1 2020
  • Synovial Sarcoma - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Synovial Sarcoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Accuronix Therapeutics Inc
  • Adaptimmune Therapeutics Plc
  • Advenchen Laboratories LLC
  • Apollomics Inc
  • Biogenera SpA
  • CoBioRes NV
  • Cue Biopharma Inc
  • Eli Lilly and Co
  • ENB Therapeutics LLC
  • Epizyme Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Immunocore Ltd
  • Incyte Corp
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc
  • MediGene AG
  • Merck & Co Inc
  • Millennium Pharmaceuticals Inc
  • OncoTherapy Science Inc
  • Pfizer Inc
  • Shanghai GeneChem Co Ltd
  • Tactical Therapeutics Inc
  • Takara Bio Inc
  • Tmunity Therapeutics Inc
  • United Immunity Co Ltd
  • Xiangxue Life Sciences
  • Zenyaku Kogyo Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll